BaCure: An Innovative Targeted Immunotherapy
High efficacy: BaCure is highly efficacious against multiple different types of cancer.
Excellent safety profile: BaCure has several built-in safety mechanisms incorporated.
Strong CD8+ T-cells response: BaCure educates CD8+ T-cells to kill metastases.
Long-lasting immunity: BaCure elicits long-lived immunity, preventing cancer recurrence.
Reduced tumour-escape mechanisms: BaCure inhibits tumour cell migration and increases apoptosis, necrosis and autophagy.
Mechanism of Action
1. Several types of cancers can develop resistance for conventional treatments. In addition, tumours employ mechanisms to hide from and inactivate the immune system. However, administration of BaCure intratumourally allows for proliferation inside the tumour.
2. BaCure then kills the tumour from the inside out by inducing necrosis, apoptosis and autophagy. In addition, it exposes the tumour to the immune system by increasing immune cell infiltration and inducing release of tumour associated antigens.
3. The effect of BaCure will result in the education of CD8+ T-cells that can kill metastases and ensure long-lived immunity, thereby reducing the likelihood of recurrence.
Necrotic Cancer Cell
Tumour specific CD8+ T-cell
Tumour associated antigen